Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02210767 · ClinicalTrials.gov registry record · NA

Effects of Walnuts on Central Blood Pressure, Arterial Stiffness Indices, Lipoproteins, and Other CVD Risk Factors

A NA study of Cardiovascular Disease, sponsored by Penn State University.

Completed
Registry status
NA
Development phase
46
Enrollment target
1
Study location

NCT02210767 is a NA study of Cardiovascular Disease that has completed, run by Penn State University. The registered enrollment target is 46 participants, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02210767, a NA study of Cardiovascular Disease, has completed, sponsored by Penn State University.

COMPLETED
Registry status
NA
Development phase
46 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the effects of walnut-derived ALA and bioactives on multiple CVD risk factors, including central blood pressure, arterial stiffness indices, inflammatory markers, urinary isoprostanes, vascular adhesion markers, and changes in lipids and lipoproteins. Gut microbiome changes due to walnut consumption will also be assessed using the 16S rRNA gene.

Conditions Studied

Interventions

  • OTHER Walnut Diet
  • OTHER Walnut Control Diet
  • OTHER Low ALA Diet

Study Locations (1)

Pennsylvania

  • Penn State University - University Park

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2014-08
Est. Completion 2018-04
Phase NA

Sponsor

Penn State University

219 total trials

What the Registry Record Tells You About NCT02210767

The ClinicalTrials.gov registry entry for NCT02210767 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (98% lower). The listed sponsor is Penn State University, which has 219 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 3 interventions - of which Walnut Diet is the first listed.

NCT02210767 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02210767 about?

NCT02210767 is a clinical study titled "Effects of Walnuts on Central Blood Pressure, Arterial Stiffness Indices, Lipoproteins, and Other CVD Risk Factors". This study will evaluate the effects of walnut-derived ALA and bioactives on multiple CVD risk factors, including central blood pressure, arterial stiffness indices, inflammatory markers, urinary isoprostanes, vascular adhesion markers, and changes in lipids and lipoproteins. Gut microbiome changes ...

What is the current status of trial NCT02210767?

This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2014-08. Estimated completion is 2018-04.

What conditions does trial NCT02210767 study?

This clinical trial studies the following conditions: Cardiovascular Disease.

What interventions are being tested in trial NCT02210767?

The interventions under investigation include: Walnut Diet (OTHER), Walnut Control Diet (OTHER), Low ALA Diet (OTHER).

Who is sponsoring clinical trial NCT02210767?

This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02210767 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.